

Warsaw, 25.02.2025.

**PRICE INQUIRY No. SEMA/59/PR94880/2025
conducted by means of market discernment**

In connection with the implementation of the project entitled "Development and development of an innovative solution - a generic drug from the group of GLP-1 receptor agonists in the treatment of type 2 diabetes" funded by the state budget from the Medical Research Agency, Polpharma Pharmaceutical Plant S.A., is requesting bids for **purchase and delivery of the reference product OZEMPIC.**

I. NAME AND ADDRESS OF THE ORDERING PARTY

Zakłady Farmaceutyczne Polpharma S.A.
19 Pelpińska St., 83-200 Starogard Gdański

II. MODE OF AWARDING THE CONTRACT

- II.1.** This order is not subject to the provisions of the Act of September 11, 2019. Public Procurement Law (i.e. Journal of Laws of 2019, item 2019)
- II.2.** Proceedings conducted by market discernment, in an expedient and economical manner in compliance with the rules:
- 1) getting the best results from given inputs;
 - 2) optimal selection of methods and means to achieve the set goals
 - 3) openness, fair competition and equal treatment of contractors

III. DESCRIPTION OF THE SUBJECT OF THE PRICE INQUIRY

- III.1.** The subject of the request for quotation is the **purchase and supply of the reference product Ozempic solution for injection from the European Union market.**
- III.2. CPV CODE 33600000-6 pharmaceutical products**
- III.3.** Scope of the price inquiry:
The shelf life of the product should be at least 15 (in words: fifteen) months from the date of delivery of the order.

PART 1 Ozempic Dose 0.25 mg from one batch in a quantity of 96 units, solution for injection in a pre-filled injector delivering 0.25 mg of semaglutide in a single administration.

PART 2 Ozempic Dose 0.25 mg from the second batch (other than Part 1) in a quantity of 33 units, solution for injection in a pre-filled injector delivering 0.25 mg of semaglutide in a single administration

PART 3 Ozempic Dose 0.25 mg from the third batch (other than Part 1 and 2) in a quantity of 9 pcs, solution for injection in a pre-filled injector delivering 0.25 mg of semaglutide in a single administration

PART 4 Ozempic Dose 0.25 mg from the fourth batch (other than Part 1, 2 and 3) in a quantity of 9 pcs, solution for injection in a pre-filled injector delivering 0.25 mg of semaglutide in a single administration

PART 5 Ozempic Dose 0.50 mg from the second batch (other than Part 1, 2, 3 and 4 – excluding batch PP5N108) in a quantity of 33 pcs, solution for injection in a factory-filled injector delivering 0.50 mg of semaglutide in a single administration

PART 6 Ozempic Dose 0.50 mg from the third batch (other than Part 1, 2, 3, 4 and 5 – excluding batch PP5N108) in a quantity of 9 pcs, solution for injection in a pre-filled injector delivering 0.50 mg of semaglutide in a single administration

PART 7 Ozempic Dose 0.50 mg of the fourth batch (other than Part 1, 2, 3, 4, 5 and 6 – excluding batch PP5N108) of 9 pcs, solution for injection in a pre-filled injector delivering 0.50 mg of semaglutide in a single administration

PART 8 Ozempic Dose 1.00 mg from the second batch (other than Part 1, 2, 3, 4, 5, 6 and 7- excluding batch PP5M878) in quantity of 9 pcs, solution for injection in a pre-filled injector delivering 1.00 mg of semaglutide in a single administration

PART 9 Ozempic Dose 1.00 mg from the third batch (other than Part 1, 2, 3, 4, 5, 6, 7 and 8 - excluding batch PP5M878) in a quantity of 9 pcs, solution for injection in a pre-filled injector delivering 1.00 mg of semaglutide in a single administration

The shelf life of the product should be at least 25 (in words: twenty-five) months from the date of delivery of the order.

PART 10 Ozempic Dose 1.00 mg of one batch of 18 units, solution for injection in a pre-filled injector delivering 1.00 mg of semaglutide in a single administration

PART 11 Ozempic Dose 0.50 mg of one batch of 21 units, solution for injection in a pre-filled injector delivering 0.50 mg of semaglutide in a single administration

- III.4.** The contracting authority allows the submission of partial bids (for individual parts, but within the same batch)
- III.5.** When placing an order with the supplier, the purchaser will confirm the series of the ordered product each time.

IV. PLACE AND DATE OF EXECUTION OF THE PRICE INQUIRY

IV.1. Deadline for completion of the subject of the request for quotation: **30 calendar days counting from the date of placing the order** by the Purchaser. Bids with a lead time of more than 30 calendar days will be rejected. The completion time must not be specified as a range. The bidder must indicate the number of weeks, expressed in single digits.

IV.2. **The purchaser plans to place the order in March 2025**, immediately after the Contractor is selected.

IV.3 The subject of the request must be delivered at the Bidder's expense to the Purchaser's premises at the following address: Zakłady Farmaceutyczne Polpharma Spółka Akcyjna, Research and Development Department, 31 Barska Street, 02-315 Warsaw.

V. REQUIREMENTS FROM CONTRACTORS

V.1 Entities for which there are circumstances are excluded from participation in the proceedings:

- described in Article 7 (1) of the Law of April 13, 2022, on special solutions to prevent support for aggression against Ukraine and to protect national security;
- described in Article 5k of Council Regulation (EU) No. 833/2014 of July 31, 2014 concerning restrictive measures in connection with Russia's destabilizing actions in Ukraine.

Method of verification of grounds/absence of grounds for exclusion:

Verification will be based on the Bidder's statement.

VI. DESCRIPTION OF THE CRITERIA THAT THE CONTRACTING AUTHORITY WILL BE GUIDED BY WHEN SELECTING A BID

VI.1. In evaluating bids, the Contracting Authority will be guided by the criteria listed:
- Net price of the subject of the contract - 100%,

$$P_C = \frac{C_N}{C_B} * 100 \text{ pkt}$$

The number of points (P_C) in the criterion "Total net price" will be calculated according to the formula:

Where:

- P_C - Number of points for the criterion "Total net price"
- C_N - of the non-rejected bids, the lowest total net bid price
- C_B - total net price of the tested offer

For evaluation, bids submitted in a currency other than PLN will be converted into PLN at the average exchange rate of the National Bank of Poland on the closing date for submission of bids.

VI.2. The maximum the Bidder can obtain is 100 points. Calculations will be made to two decimal places, for each part separately.

VII. PLACE AND DEADLINE FOR SUBMITTING BIDS

VII.1. Bids must be submitted by the **deadline of 05.03.2025.**

- in electronic form (in the form of a scanned signed document or a document signed with a qualified signature) to the following address: dorota.pielak@polpharma.com

VII.2. Submission of a bid will be considered successful if a complete bid is received at the e-mail box with the above address by the deadline defined in the point VII.1.

VII.3. Bids submitted after the deadline will not be considered.

VIII. DESCRIPTION OF BID PREPARATION

VIII.1. The bidder should prepare one price offer in accordance with the model form attached as **Annex 1** to the request.

VIII.2. Submission of more than one bid for a given part will result in rejection of all bids submitted by the Seller.

VIII.3. The bid should be prepared in Polish or English.

VIII.4. The bid must be signed by persons authorized to represent the Bidder or acting under a power of attorney. The power of attorney must be attached to the bid.

VIII.5. Bidders are required to carefully review the information contained in the Price Request.

VIII.6. The bidder shall bear all costs associated with the preparation and submission of the bid.

VIII.7. Until the deadline for submission of bids, the Procuring Entity reserves the right to amend or supplement the contents of this price inquiry.

VIII.8. A bidder submitting a bid shall remain bound by it for a period of 60 calendar days counting from the deadline for submission of bids.

VIII.9. The minimum payment term of the invoice is 30 days from the date of the invoice. Bids with payment terms of less than 30 days will be rejected.

VIII.10. The bidder may amend or withdraw its bid before the deadline for submission of bids.

VIII.11. Bidders are required to carefully review the information contained in the Price Request.

VIII.12. For matters related to this inquiry, please contact the Contracting Authority, e-mail: dorota.pielak@polpharma.com

IX. OTHER INFORMATION

- IX.1.** No verbal or telephonic information, explanations or answers to inquiries addressed to the Purchaser are provided.
- IX.2.** Any questions regarding this inquiry should be submitted by email to the address indicated in the point VIII.12. no later than 3 days before the deadline for submission of bids.
- IX.3.** Responses to questions and the detailing of the Inquiry resulting from questions from potential Bidders will be sent to the entity that sent the question.
- IX.4.** In the course of examination and evaluation of bids, the Purchaser may request from the Bidder supplements (if this does not violate competitiveness) and clarifications regarding the content of the submitted bids. He may also request correction of obvious mistakes and calculation errors.
- IX.5.** The Purchaser reserves the right to check, in the course of evaluating the offer, the credibility of the documents, statements, lists, data and information presented by the Bidders.
- IX.6.** **The Procuring Entity reserves the right to negotiate bids with the Bidder** whose bid obtains the highest number of points, especially if the price offered by the Bidder exceeds the budget allocated by the Procuring Entity for the execution of the contract.
- IX.7.** If two or more Bidders obtain the same number of points, the bid with the most favorable environmental and climate impact will be selected. For this purpose, the Purchaser has the right to call on the Bidders whose bids received the highest final number of points to supplement their bids by providing the information indicated by the Purchaser regarding the environmental impact of the subject of the bid.
- IX.8.** The Procuring Entity reserves the right to cancel the purchasing procedure without giving any reason.
- IX.9.** In the event of cancellation of the proceedings, the Bidder shall not be entitled to a claim for reimbursement of the costs of participation in the proceedings.

X. LIST OF ANNEXES

The following documents are attached to this Price Request:

Annex Designation	Name of the Annex
Appendix 1	Sample price form

Appendix No. 1 to the Price Request No. SEMA/59/PR94880/2025

PRICING FORM

Bidder:

Full name (company) or first and last name	
Registered office/place of residence/address of main place of business	
The e-mail address to which the Employer should send correspondence related to the price inquiry	
NIP	
REGON	
Phone	
Contact person for the Purchaser	

We offer to perform the subject of the contract **for the purchase and delivery of the reference product OZEMPIC**, *in* accordance with the requirements of the Price Request, at a **price:**

Part of	Subject of the price inquiry Full description	i.m.	Quantity	Net price PLN/ EUR/ USD* per IU.	Total net value PLN / EUR /USD*.	Total gross value PLN / EUR / USD*	Delivery time [number of calendar days from date of order, maximum 30 days].
1							
2							
3							
4							
5							
6							



7								
8								
9								
10								
11								
12								
13								
14								
15								

*select the appropriate currency

Payment term of invoices is days

The bidder has the status of SME / Large Entrepreneur.**

** (delete as appropriate)

At the same time, we declare that:

- a. we have familiarized ourselves with the Request for Quotation and its attachments and do not raise any objections, and we have acquired the necessary information to prepare our offer,
- b. The price includes a lump sum remuneration for all the Seller's obligations necessary to complete the subject of the Price Request,
- c. we consider ourselves bound by this bid for a period of 60 calendar days from the deadline for submission of bids ,
- d. circumstances do not apply to us :
 1. described in Article 7 (1) of the Law of April 13, 2022, on special solutions to prevent support for aggression against Ukraine and to protect national security;



AGENCJA
BADAŃ
MEDYCZNYCH



2. described in Article 5k of Council Regulation (EU) No. 833/2014 of July 31, 2014 concerning restrictive measures in connection with Russia's destabilizing actions in Ukraine.

.....
(place and date)

.....
(Signature of person(s) authorized to make a
statement of intent on behalf of the Bidder)